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Cellular/Molecular
Mechanism of Partial Agonism at NMDA Receptors for a
Conformationally Restricted Glutamate Analog
Kevin Erreger,1Matthew T. Geballe,2 ShashankM. Dravid,1 James P. Snyder,2David J. A. Wyllie,3 and
Stephen F. Traynelis1
1Department of Pharmacology, Emory University School of Medicine, Rollins Research Center, and 2Department of Chemistry, Emory University, Atlanta,
Georgia 30322, and 3Division of Neuroscience, University of Edinburgh, Edinburgh EH8 9JZ, United Kingdom
TheNMDA ionotropic glutamate receptor is ubiquitous inmammalian central neurons. Because partial agonists bind to the same site as
glutamate but induce less channel activation, these compounds provide an opportunity to probe themechanism of activation of NMDA-
type glutamate receptors. Molecular dynamics simulations and site-directed mutagenesis demonstrate that the partial agonist homo-
quinolinate interacts differently with binding pocket residues than glutamate. Homoquinolinate and glutamate induce distinct changes
in the binding pocket, and the binding pocket exhibits significantly more motion with homoquinolinate bound than with glutamate.
Patch-clamp recording demonstrates that single-channel activity induced by glutamate or by homoquinolinate has identical single-
channel current amplitude and mean open-channel duration but that homoquinolinate slows activation of channel opening relative to
glutamate.We hypothesize that agonist-induced conformational changes in the binding pocket control the efficacy of a subunit-specific
activation step that precedes the concerted global change in the receptor–channel complex associated with ion channel opening.
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Introduction
TheNMDA subtype of ionotropic glutamate receptors comprises
both NR1 and NR2 receptor subunits and plays a major role in
both physiological and pathophysiological processes in the brain
(for review, see Dingledine et al., 1999). The co-agonists glycine
and glutamate are both required for channel activation, and the
binding sites for glycine and glutamate are contained within the
NR1 and NR2 subunits, respectively. The crystallization of the
agonist-binding S1S2 domain for both the AMPA receptor sub-
unit GluR2 (Armstrong et al., 1998; Armstrong and Gouaux,
2000; Jin et al., 2002) and, more recently, the NMDA receptor
subunit NR1 (Furukawa and Gouaux, 2003) has provided direct
insights into the molecular basis for agonist binding (for review,
see Gouaux, 2004; Mayer and Armstrong, 2004). Crystallization
of the agonist binding domain for GluR2 with a series of agonists
demonstrated that the two lobes of the agonist binding domain
display a greater degree of domain closure when the binding site
is occupied by glutamate than they do when a partial agonist
occupies this site (Jin and Gouaux, 2003; Jin et al., 2003). Previ-
ous work by Jin et al. (2003) relating structure to agonist efficacy
suggests that the degree of domain closure correlates with func-
tional activity. This study also provided additional evidence for
the hypothesis that individual AMPA receptor subunits make
incremental contributions to the gating of the ion permeation
pathway (Rosenmund et al., 1998; Jin et al., 2003). However,
NMDA receptors differ significantly from AMPA receptors in
their functional properties and perhaps even in fundamental as-
pects of activation and gating (for review, see Erreger et al., 2004).
Previous results with NR1/NR2B NMDA receptors suggest that
there are subunit-specific pregating steps that can be modulated
specifically by partial agonists acting at the glutamate site on
NR2B or the glycine site on NR1 (Banke et al., 2005).
In this study, we evaluate the mechanism by which the con-
formationally restricted partial agonist homoquinolinate acti-
vatesNR1/NR2A receptors.We usemolecular dynamics (MD) to
predict how homoquinolinate interacts with the binding pocket
in NR2A and test these predictions using site-directed mutagen-
esis. Additionally, we use MD to predict how the position and
mobility of residues of the binding pocket are influenced by ho-
moquinolinate compared with glutamate. We use patch-clamp
recording to determine in detail the effects of the partial agonist
homoquinolinate on channel activity. We propose a model of
channel activation and gating based on independent subunit pre-
gating steps, followed by concerted pore dilation. Our analyses
suggest that there aremultiple activating conformational changes
preceding channel gating and that at least one of these pregating
steps is faster for channels activated by glutamate than by the
partial agonist homoquinolinate because of differences in how
these agonists interact with the binding pocket.
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Materials andMethods
Electrophysiological recording from human embryonic kidney 293 cells and
Xenopus oocytes. Human embryonic kidney 293 (HEK293) cells were
maintained and transiently transfected by the calcium phosphate
method with cDNA encoding NR1-1a (GenBank accession numbers
U11418 and U08261; pCIneo vector; hereafter NR1), NR2A (D13211;
pCIneo), and green fluorescent protein at a ratio of 1:2:1 (0.2 g/ml
NR1) for 4–12 h, as described previously (Zheng et al., 1998). Currents
from outside-out patches were digitally recorded with pClamp8 software
using an Axopatch 200B amplifier (Molecular Devices, Union City, CA).
Single-channel records were filtered at 5 kHz using an eight-pole Bessel
filter (3 dB; FrequencyDevices,Haverhill,MA) anddigitized at 40 kHz.
Macroscopic currents were filtered at 2–5 kHz and digitized at 20 kHz.
The extracellular solution consisted of (in mM) 150 NaCl, 10 HEPES, 0.5
CaCl2, 3KCl, and 0.01 EDTA supplementedwith 50Mglycine and 1mM
glutamate, unless noted otherwise (pH 7.3, 23°C). Formost experiments,
the agonist-containing extracellular solution was made from ultra-pure
salts with an Mg2 concentration of 0.2 M measured using induc-
tively coupled plasma-mass spectrometry by the Laboratory for Environ-
mental Analysis at the University of Georgia (Athens, GA). Single-
channel data recordedwith normal salts was included in the final analysis
because the measured Mg2 concentration was 1 M, and the mean
channel open time was not significantly different in paired comparisons
of normal and ultrapure salts in the same patches expressing NR1/NR2A
(p  0.05; n  6). The internal solution consisted of the following (in
mM): 110 Cs gluconate, 30 CsCl2, 5 HEPES, 4 NaCl, 0.5 CaCl2, 2 MgCl2,
5 BAPTA, 2 Na-ATP, and 0.3 Na-GTP, pH adjusted to 7.35 with CsOH.
Rapid solution exchange was achieved with a two-barrel theta glass pi-
pette controlled by a piezoelectric translator (Burleigh Instruments, Fish-
ers, NY); junction currents were used to estimate speed of solution ex-
change after recordings and typically had 10–90% rise times of 0.3–1.0
ms (7- to 21-fold faster than NMDA receptor rise times).
Oocytes from Xenopus laevis were isolated, injected with NMDA re-
ceptor cRNA synthesized in vitro, and recorded under voltage clamp as
described previously (Traynelis et al., 1998). Briefly, oocytes were in-
jected with 5–10 ng of cRNA at a 1:2 ratio of NR1:NR2A. Glutamate- or
homoquinolinate-evokedmembrane currents were recorded at40mV
in the presence of 50 M glycine 24–72 h after injection. The recording
solution contained (in mM) 90 NaCl, 3 KCl, 10 HEPES, 0.01 EDTA, and
0.5 BaCl2 (23°C); the pH was adjusted with NaOH, and recording elec-
trodes were filled with 0.3 M KCl.
Single-channel and macroscopic analysis. Single-channel analysis was
performed using QUB software (www.qub.buffalo.edu) to idealize
records and fit kinetic models to idealized single-channel data. For his-
togram fitting, the data were divided into uniform segments (0.5 s), and
any segment with simultaneous multiple channel openings was dis-
carded. Records were idealized with the segmentation k-means
algorithm (Qin, 2004). Dwell-time distributions were fit to multiple ex-
ponential kinetic components using ChanneLab (http://www.
pharm.emory.edu/straynelis/Downloads). Each individual patch con-
tained, on average, 5796 events for glutamate and 2673 events for
homoquinolinate. For maximum interval likelihood (MIL) (Qin et al.,
1996), fitting data were idealized and segmented by QUB software using
a critical gap time (Tcrit) thatminimized the total number ofmisclassified
events (Jackson et al., 1983) (EKDIST software provided by D.
Colquhoun, University College London, London, UK). The Tcrit calcu-
lated from patches that contained a single active NR1/NR2A channel was
30 ms (Erreger et al., 2005). Idealized activations were then fit by hidden
Markov models using the MIL method. Macroscopic response wave-
forms obtained in outside-out patches were averaged among patches.
The average macroscopic glutamate response waveform was then nor-
malized to the measured peak open probability determined from brief
application of maximally effective concentration of agonist in patches
that contain one active channel (Erreger et al., 2005). The homoquinoli-
nate waveform was scaled relative to glutamate using the relative peak
currents observed for glutamate and homoquinolinate in the same
patches. Hidden Markov models were simultaneously fitted (Chan-
neLab; least squares criterion) to multiple waveforms obtained for both
short and long pulses of agonist at both high and low concentrations.
This involved determination of the sum of squares difference between
simulation and data for all fitted waveforms at each iteration within the
simplex algorithm. In other experiments, the mean macroscopic time
course was fitted by the sum of two exponential functions:
Response Amplitude1 exp(time/1)
 Amplitude2 exp(time/2) steady state.
The ratio F test was used to determine whether the meanmacroscopic
relaxation (200 data points selected at a fixed interval) was fitted signifi-
cantly better by one or by the sum of two exponential functions.
Homology modeling andMD. A homology model of glutamate docked
into the S1–S2 region ofNR2A (GenBank accession numberD13211) has
been described previously (Chen et al., 2005). Glutamate was removed
from the binding site, and homoquinolinate was built in its place, with
the nitrogen of the aromatic ring left unprotonated. The pKa for this
ionizable group was calculated to be 5.82 using Solaris software (version
4.67; Advanced Chemistry Development, Toronto, Ontario, Canada).
All three structures (glutamate docked in S1–S2, homoquinolinate
docked in S1–S2, and the nonliganded/apo S1–S2) were simulated using
theGromos96 force field and solvatedwith the simple point charge water
model. A hydrated cube (7 nm on each side; volume, 345 nm3) con-
taining11,000 water molecules was built around each structure. Each
hydrated complex was energy minimized to remove any poor contacts,
subjected to 20 ps of position-restrained MD at 300 K to allow water to
soak into the structure. To resolve any high-energy contacts, the com-
plexes were subjected to low-temperature unrestrained MD over very
small time steps using the GROMACS package (Berendsen et al., 1995;
Lindahl et al., 2001). Each system was run at 20 K for 3 ps, using a time
step of 1 fs. A frame was then selected as the starting point for a subse-
quent 20 K simulation. Repeated iterations allowed the structures to find
relaxed states without propagating large forces (i.e., from steric clashes)
through the entire complex. Further MDwas then performed on each of
the three structures at 200 K using a time step of 2 fs. These simulations
were extended to 500 ps of unrestrainedMD. Structures for equilibrated
complexeswere calculated by averaging the final 150 ps of the simulation.
Statistical analysis. Student’s t test (two tailed) was performed in Excel
software for statistical comparisons ( p  0.05 was considered signifi-
cant). Data are expressed as mean SEM.
Results
Homoquinolinate is a partial agonist for NR1/NR2A
We used two-electrode voltage-clamp recording of steady-state
current responses from recombinant NR1/NR2A receptors ex-
pressed inXenopus oocytes to quantify the potency and efficacy of
homoquinolinate relative to the maximal current evoked by a
saturating concentration of glutamate. Our results indicate that
homoquinolinate is a candidate partial agonist when studied in
oocytes, able to evoke70% of the maximal response produced
by glutamate (n  19) (Fig. 1A, Table 1). This submaximal re-
sponse by 1 mM homoquinolinate could be converted to a max-
imal response by coapplication of homoquinolinate with increas-
ing concentrations of glutamate (n  5) (Fig. 1A), confirming
that homoquinolinate is a partial agonist. We subsequently eval-
uated the efficacy of rapidly applied homoquinolinate relative to
glutamate for activation of NR1/NR2A receptors in outside-out
patches isolated fromHEK293 cells (Fig. 1B). Comparison of the
peak responses for a maximally effective concentration of homo-
quinolinate to the average of control and recovery responses to a
maximally effective concentration of glutamate showed that ho-
moquinolinate evoked 63 4% (n 4) of the glutamate-evoked
NR1/NR2A current response in mammalian cells. The relative
efficacy of homoquinolinate for peak currents in outside-out
patches from HEK293 cells was similar to that for steady-state
currents in oocytes. We have shown previously that NR1/NR2A
receptors in outside-out patches have a peak open probability of
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0.50 when activated by a maximally effective concentration of
glutamate (Erreger et al., 2005). From this measurement and the
relative efficacy of homoquinolinate to glutamate, we estimate
that themaximumopen probability for homoquinolinate activa-
tion of NR1/NR2A receptors is 0.31. The EC50 value for gluta-
mate (4.6 M) was lower than for homoquinolinate (24.4 M)
(Table 1).
Activation rate of NR1/NR2A by homoquinolinate is slower
than for glutamate
Tobetter understand themechanismbywhichNR2A-containing
receptors become activated by agonist, we performed recordings
under voltage clamp of macroscopic NR1/NR2A current re-
sponses in excised outside-out patches. Current responses to pro-
longed application of both glutamate and homoquinolinate de-
cayed with a mean time course that could be described by one or
two exponential components, depending on the patch. However,
it should be noted that NMDA channels in excised patches ex-
hibit substantially greater desensitization (independent of gly-
cine, calcium, or zinc) than NMDA channels recorded in whole-
cell or perforated-patch recording mode (Zheng et al., 2001;
Erreger et al., 2005). When a single exponential time constant is
fitted to the relaxation for all patches, the mean time constant for
glutamate (187  64 ms; n  14 patches) was not significantly
different than for homoquinolinate (193 20 ms; n 14). The
time course was significantly better fitted in the majority of
patches (seven of nine patches tested) by the sum of two expo-
nential components (p  0.001). The averaged composite time
course decayed with time constants (and relative amplitudes) of
60ms (38%) and 257ms (62%) for glutamate, whichwere similar
to the time constants of 82 ms (28%) and 229 ms (72%) describ-
ing homoquinolinate-induced desensitization. In addition, the
steady state-to-peak current ratio was not significantly different
between glutamate (0.15  0.03; n  14) and homoquinolinate
(0.13 0.02; n 12). These data suggest that the rate and degree
of desensitization induced by the two agonists is similar. We also
measured the time course for deactivation after a brief (5–15ms)
pulse of maximal concentration of agonist. We found that the
time constant describing deactivation after brief glutamate appli-
cation (36.1  2.6 ms; n  8) was significantly slower than that
describing deactivation from homoquinolinate (21.7  4.0 ms;
n  4; p  0.011; unpaired t test). In addition, the 10–90% rise
time of macroscopic currents (Fig. 1C) in response to rapid ap-
plication of a saturating (1 mM,40-fold EC50 value) concentra-
tion of homoquinolinate (12.2  0.8 ms; n  14) was signifi-
cantly slower than for saturating glutamate (6.8 0.8ms; n 16;
p 0.0003; unpaired t test). Identical results were obtained in a
subset of patches in which rise times were measured for both
glutamate- and homoquinolinate-evoked currents in the same
patch (homoquinolinate, 12.3 1.4ms; glutamate, 8.0 0.7ms;
p 0.016; paired t test; n 8). These data are consistent with the
hypothesis that the main determinant of partial agonism is not a
difference in desensitization but rather a specific effect on con-
formational changes that precede or control channel opening.
Modeling of glutamate and homoquinolinate interaction with
the agonist binding pocket
To better understand the nature of the reduced potency and re-
duced efficacy of homoquinolinate, we used MD applied to a
homology model of the S1S2 domain of NR2A docked to either
glutamate or homoquinolinate (seeMaterials andMethods). Fig-
ure 2A illustrates the alignment used to generate a homology
model of the glutamate binding domain of NR2A (Chen et al.,
2005) based on a crystal structure of the NR1 glycine binding
domain (Furukawa and Gouaux, 2003). The -helices and
-sheets were labeled according to the NR1 structure (Furukawa
and Gouaux, 2003). Figure 2B–D superimposes the model of the
NR2A S1S2 binding domain with either glutamate or homo-
quinolinate docked using MD. Figure 3A shows the glutamate
-carboxyl anchored by Arg499 plus a backbone nitrogen from
Ser670 (Chen et al., 2005). Arg499 also makes an important hy-
drogen bond with the backbone carbonyl of Thr494 (data not
shown). The-amino group of glutamate is hydrogen bonded by
the hydroxyl of Tyr742 (Fig. 3B) and has the potential for favor-
able interactions with the hydroxyls of Ser492 and Thr494 and
the carboxylate of Asp712 (data not shown). The -carboxyl in-
teracts with the hydroxyl groups from Ser670 and Thr671, with
additional support from the Thr671 backbone nitrogen (Fig. 3C).
Homoquinolinate is a conformationally restricted glutamate an-
alog that contains two carboxyl groups and a secondary amine
embedded in an aromatic ring with side-chain bond angles of
120° compared with 109° for glutamate. Figure 2, B and C, illus-
trates the superposition of the docked agonists, which show sim-
ilar positioning for the three functional groups. However, several
differences between simulated homoquinolinate and glutamate
binding are apparent. For example, the aromatic ring of homo-
quinolinate takes up more space than glutamate, with resulting
displacement of residues in the pocket. This can be visualized by
the apparent displacement of Tyr742 by homoquinolinate (Fig.
3B). In addition, Ser670 changes its primary hydrogen-bonding
Figure 1. Homoquinolinate is a partial agonist for NR1/NR2A NMDA receptors. A, Left,
Steady-state, dose–response relationship for NR1/NR2A currents in Xenopus oocytes normal-
ized to 100M glutamate (50M glycine;40 mV). For glutamate, the EC50 value is 4.6M,
and the Hill slope is 1.4 (n 11). For homoquinolinate, the EC50 value is 24.4M, and the Hill
slope is 1.2 (n19). Right, The decreased current inducedbyhomoquinolinate canbe restored
to full activity by coapplication of increasing concentrations (in millimolar) of glutamate, indi-
cating that the reduced efficacy of homoquinolinate is attributable to an effect at the glutamate
binding site (n 5). The inset shows a raw current trace from one representative oocyte. B,
Example of NR1/NR2A currents recorded under voltage clamp evoked in response to rapid
application of 1 mM glutamate or 1 mM homoquinolinate to outside-out patches isolated from
HEK293 cells (VHOLD,60mV; 1 s applicationduration). The relative amplitude of peak currents
evoked in the samepatch for homoquinolinate relative to glutamate is 62.8 4.3% (n 4). C,
The rise times are significantly slower for homoquinolinate-activated currents compared with
those activated by glutamate. The inset shows the mean normalized rise waveforms averaged
among all patches. The number in parentheses indicates the number of cells. *p 0.001,
unpaired t test. GLU, Glutamate; HQ and Homoquin, homoquinolinate.
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partner from the -carboxyl of glutamate to the -carboxyl in
homoquinolinate (Fig. 3C). This change in hydrogen bonding of
the -carboxyl identified by MD analysis, if correct, would be
predicted to alter homoquinolinate sensitivity to mutation of S2
contact residues by comparison with glutamate. We directly
tested this idea by generating concentration–response curves for
twomutant NR2A receptors, NR2A(S670G) and NR2A(T671A).
Consistent with predictions from MDmodeling, the NR2A mu-
tation S670G in the S2 domain shifted the EC50 value for homo-
quinolinate by 15-fold, much less than the 92-fold potency shift
for glutamate (Table 1). Similarly, the S2 NR2Amutation T671A
only shifted homoquinolinate EC50 by 6-fold compared with
645-fold for glutamate (Table 1) (Chen et al., 2005). These data
support the idea that the contact residues for the carboxylates of
homoquinolinate differ from those for glutamate, lessening the
contribution of Ser670 and Thr671 to the stabilization of homo-
quinolinate in the binding pocket. MD modeling also predicts
that Ser492makes intermittent hydrogen bonds with the proton-
ated amine of glutamate. However, no such hydrogen bonds are
observed between Ser492 and the unprotonated nitrogen of ho-
moquinolinate, suggesting that mutation of Ser492 should have
differential effects on glutamate and ho-
moquinolinate EC50. As predicted by MD
analysis, the receptors comprising
NR2A(S492A) showed a 32-fold increase in
glutamate EC50 but only an 8-fold increase
in homoquinolinate EC50. These func-
tional data are thus consistent with the re-
sults of MD modeling.
The bulkier size of homoquinolinate
and its displacement of residues such as
Tyr742 suggest that homoquinolinatemay
not be held as tightly in the pocket as glu-
tamate. If this is the case, we predict that
the EC50 value determined from func-
tional data and the molecular motion of
side chains comprising the pocket will
both increase. To evaluate this hypothesis,
we analyzed the root mean square (rms)
deviations of the atomic positions of 22
residues comprising the binding pocket
over the final 150 pS of MD. With the ex-
ception of Tyr742, which fluctuates in and
out of a hydrogen bond with the amino
group of glutamate, these residues showed
considerablymoremotion around docked
homoquinolinate (mean ratio rmsHQ/
rmsGLU for each residue, 1.33) than
around both glutamate-bound and apo
structures during MD runs (Fig. 4) (apo
data not shown). The greatest contribu-
tion to pocket motion came from the S2
residues 669–674 (rmsHQ/rmsGLU, 1.73)
that secure the carboxylates of homo-
quinolinate and more distant residues that make up the top of
helix F. This is the same region that shows wide variation in
hydrogen binding between glutamate and homoquinolinate
-carboxyl, which act as a bridge across the binding pocket (Figs.
3C, 5).Unlike glutamate, homoquinolinate binding in this region
involves a water bridge to Asp712 that will increase intrapocket
motion (Fig. 5C). Additional determinants of the increased rms
values may also reflect increased side-chain motion that results
from ongoing steric contacts between homoquinolinate and res-
idues within the binding pocket. This increased motion suggests
a decreased binding stability for homoquinolinate compared
with glutamate. Increasedmotion for homoquinolinate also sug-
gests an increased KD value, consistent with the experimentally
determined increased EC50 value for homoquinolinate compared
with glutamate (Table 1).
Translation of agonist binding to channel opening
A number of interesting features of the S2 backbone helix F are
apparent in our simulations. First, the displacement of helix F
from helix G does not change considerably between the apo
state and the glutamate-bound state (Fig. 5). In addition, ho-
Table 1. Potency for glutamate and homoquinolinate at wild-type andmutant receptors
Receptor Glu EC50 (M) Glu Hill slope n HQ EC50 (M) HQ Hill slope n IMAX HQ/Glu Glu EC50mut/wt HQ EC50mut/wt
NR1/NR2A 4.6 1.4 11 24.4 1.2 19 0.72
NR1/NR2A-S670G 421 1.4 12 151 1.1 9 0.51 92 6
NR1/NR2A-T671A 2967 1.3 5 384 0.7 9 0.10 645 16
NR1/NR2A-S492A 146 1.2 6 202 1.2 6 0.67 32 8
Parameters measured from steady-state recording of indicated subunits expressed in Xenopus oocytes are shown. n is the number of cells. IMAX HQ/Glu is the ratio of maximal current induced by homoquinolinate relative to glutamate at a
saturating agonist concentration in the same cell. Glu, Glutamate; HQ, homoquinolinate; wt, wild type; mut, mutant.
Figure 2. MD simulation of glutamate or homoquinolinate docking to a homology model of the NR2A S1S2 agonist binding
pocket. A, Alignment used for construction of the homology model for NR2A. B, Superposition of MD simulation of glutamate
(orange) or homoquinolinate (gray) docked to S1S2. ATD, N-terminal domain; M1–M4, membrane domains 1–4. C, Superposi-
tion of glutamate and homoquinolinate shown without amino acid residue side chains emphasizes superposition of functional
groups.D, An expanded view shows differential displacement of helix Fwhen glutamate versus homoquinolinate is docked in the
binding pocket. Letters F–I indicate helices. PDB files of the coordinates for both models can be found at http://www.
pharm.emory.edu/straynelis/StructuralModels/.
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moquinolinate appears not only to dis-
place helix F (Fig. 2D), compared with
glutamate, but to open up more space
within the binding pocket, suggesting
that homoquinolinate can propagate
longer range perturbations through the
domain structure. Furthermore, contact
between helix F and other elements of
the secondary structure is lost with ho-
moquinolinate in the pocket (Fig.
5B,C). These contacts are formed
through three hydrogen bonds in the
apo-NR2A that connect helix F to
-sheet 12 and a loop between -sheets 5
and 6. The hydrogen bond between
Ser670 and Asp712 is lost after glutamate
or homoquinolinate binding. Homo-
quinolinate binding further disrupts the
hydrogen bonds between Thr671 and
the backbone oxygen of Ile710 as well as
between the backbones of Asn668 and
Gly467 (Fig. 5C). In the NR2A–gluta-
mate complex, these contacts are essen-
tially retained by preservation of the backbone hydrogen bond
between Asn668 and Gly467 and a frequent hydrogen bond
between the -carboxyl of glutamate and the backbone hydro-
gen of Asp712. The homoquinolinate system substitutes the
latter interaction with a trio of water molecules (Fig. 5C). The
direct contacts between helix F and the neighboring secondary
structure are not found in the averaged structure with homo-
quinolinate. One intriguing, yet speculative, hypothesis is that
this uncoupling of helix F to the rest of the protein may play a
role in the reduced translation of binding energy to displace-
ment of gating elements by homoquinolinate, which may in
part contribute to its reduced ability to open the channel (see
below).
Homoquinolinate alters NR1/NR2A
single-channel properties
To examine the mechanism of activation by glutamate and ho-
moquinolinate, single-channel recordings were made from
outside-out patches. Channel activity was evoked by steady-state
application of a maximally effective concentration of either glu-
tamate (1 mM) or homoquinolinate (1 mM) (Fig. 6). The single-
channel chord conductance and themean channel open duration
were the same for both agonists. These twomeasures suggest that
the properties of the open-channel conformation are not directly
dependent on the identity of the agonist. The primary difference
among the functional properties of the single-channel activations
caused by the two agonists was within the distribution of the shut
times, which was described by at least four exponential compo-
nents. There were no significant differences in the relative area of
any of the four shut-time components between glutamate and
homoquinolinate (p  0.05; paired t test; n  7). The shortest
shut-time component, which we estimate to be0.1 ms, was too
near the limit of our recording resolution to be measured pre-
cisely in some patches. The next fastest time constant (shut time
2) (Fig. 6, gray arrow) was not significantly different between
agonists. Shut time 3 (Fig. 6, black arrow) was significantly
longer for homoquinolinate-induced activity than for glutamate-
induced activity. A similar shift in the analogous shut-time com-
ponent has been described previously with partial agonists for the
glutamate site for NR1/NR2B and was hypothesized to reflect a
slowing of a single conformational change within the NR2 sub-
unit (Banke and Traynelis, 2003). Changes in the fourth shut-
time component (4) could not be interpreted, because this com-
ponent likely contained time periods between closure of one
channel and opening of another channel, given that the total
number of channels contained within the patches we recorded
from was unknown and was unlikely to be equal for all patches.
The relative area of this fourth component of the shut-time dis-
tribution is substantial (glutamate, 10  3%; homoquinolinate,
16 3%; n 7). Nonetheless, we suggest that this kinetic com-
ponent reflects in part the time course of a desensitization-related
process andnot the fundamentalmechanismof channel opening.
We consider the fitting of shut-time distributions as a first-pass
model-independent analysis of agonist-specific features of chan-
nel gating.We subsequently fitted the sequence of single-channel
events with an explicit kinetic model to attempt to draw mecha-
nistic conclusions from the data.
Homoquinolinate slows a specific pregating step
As indicated above, the only consistent feature of single-channel
open and closed time histograms that changed when channel
activity was evoked by homoquinolinate or glutamate was the
Figure 3. Comparison of glutamate and homoquinolinate binding. A, Glutamate and homoquinolinate docking are shown
with-carboxyl and-carboxyl hydrogen bond contacts. B, Displacement of Tyr742 illustrates the steric clash produced by the
aromatic ring of homoquinolinate when docked into the glutamate binding pocket. C, Ser670 is reoriented to interact with the
-carboxyl of homoquinolinate compared with the hydrogen bond it forms with the-carboxyl of glutamate.
Figure 4. Increased atomic motion within the binding pocket for homoquinolinate. The SD
(i.e., rms) of atomic position is shown in pseudocolor for residues that comprise the agonist
binding pocket, with cold colors (blue) representing low rms and hot colors (red) representing
high rms. Results are shown after MD runs for glutamate and homoquinolinate. The range of
rms values for residues comprising the binding pocket were 0.0257–0.1045 nm for glutamate
and 0.0316–0.0823 nm for homoquinolinate.
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value of the third exponential component in the shut-time distri-
bution. Such a change could reflect any number of features of the
NMDA receptor activation process. To circumvent the indirect
nature of inferences made from histogram fitting, we used max-
imum likelihood fitting of explicit models that encapsulated our
working hypothesis of NMDA receptor activation to single-
channel records (Banke and Traynelis, 2003; Erreger et al., 2005).
A number of previous studies have convincingly argued that at
least two pregating kinetically distinct conformation changes are
required before NMDA receptors can open (Gibb and
Colquhoun, 1991; Wyllie et al., 1998; Banke and Traynelis, 2003;
Popescu and Auerbach, 2003; Popescu et al., 2004; Erreger et al.,
2005).We therefore used hiddenMarkovmodeling of our single-
channel data to explore whether differences exist between
glutamate-evoked or homoquinolinate-evoked channel transi-
tion rates for the conformational changes that precede NMDA
channel opening. Data were analyzed by subdividing records on
the basis of a critical time (30 ms) that was calculated to allow
identification of individual activations (Erreger et al., 2005). That
is, the critical closed times were used to separate open and closed
times within an activation from closed times between two differ-
ent activations (see Materials and Methods). The idealized se-
quence of channel eventswas then fittedwith amodel postulating
twopregating conformational changes (a fast step forNR1, a slow
step for NR2), followed by rapid pore dilation. The hypothesized
assignment of individual subunits to the kinetic steps is based on
previous work demonstrating the pharmacological sensitivities
of these steps to agonists acting at the glycine or glutamate site in
NR1/NR2B receptors, aswell as the sensitivity of these steps to the
identity of the NR2 subunit (Banke and Traynelis, 2003; Erreger
et al., 2005). Two directly interconverting open states were in-
cluded to better describe the distribution of open-channel dwell
times (Popescu et al., 2004).
We directly fit this explicit kinetic model to the specific se-
quence of channel openings and closings. Scheme 1 (Fig. 7) pos-
tulates that the NR1 and NR2 subunits activate independently
and that both must be active before the channel pore opens. The
rates “f” (fast) and “s” (slow) that are shown are for the hypoth-
esized transition between an agonist-bound “inactive” state and
an agonist-bound “active” state for the NR1 (f) and NR2 (s)
subunits (Banke and Traynelis, 2003; Erreger et al., 2005). Be-
cause the recordings were performed in the continuous presence
of a saturating concentration of both glutamate and glycine, no
explicit binding steps are included and full occupancy of ligand
binding sites is assumed. Desensitized states are also omitted be-
cause data were segmented with a critical shut time to remove
desensitized shut durations. We fitted scheme 1 to the sequence
of channel openings in each patch for sequential application of
both glutamate and homoquinolinate and found that our work-
ing model fit data from each patch well, with limited variability
between rate constants among patches. The average log likeli-
hood (a measure of the quality of the fit of the model to the data)
value was identical when the model was fitted to either single-
Figure 5. -Carboxyl bridges the agonist binding pocket. A shows the MD run of the apo protein without agonist. Note the hydrogen bonds between Ser670 and Thr671 with Asp712 and a
backbone nitrogen.B shows how the-carboxyl inserts itself into this region, interrupting these hydrogen bonds to form a hydrogen-bonded bridge between Ser670/Thr671 and Asp712. C shows
how the orientation of homoquinolinate requires waters to form this same bridge, which results in increased mobility in this region of the pocket (Fig. 4). Only the bridging water molecules are
shown, although all models were fully hydrated during MD. Letters F and G indicate helices.
Figure 6. Rate of activation of by homoquinolinate is slower than for glutamate. A, Left,
Single-channel current activity elicited in an outside-out patch in response to steady-state
applicationof 1mMglutamate. The recordingwasmade in thepresenceof 50Mglycine and10
M EDTA at a holding potential of80 mV, and downward deflections reflect channel open-
ing. Right, The distribution of shut times from the same patch as the sample trace is shown and
can be fit by four exponential components. B, The corresponding data are plotted for 1 mM
homoquinolinate in the same patch. The single-channel chord conductance was identical for
both agonists (glutamate, 62.6 1.7 pS; homoquinolinate, 60.9 2.3 pS; n 7), as was the
mean channel open duration (glutamate, 3.72 0.39ms; homoquinolinate, 3.62 0.31ms;
n  7). The time constant for the second shut-time component (2; gray arrow) was not
significantly different between agonists (glutamate, 0.489  0.025 ms; homoquinolinate,
0.455  0.074 ms; n  7). Shut time 3 (black arrow) was significantly longer for
homoquinolinate-induced activity than for glutamate-induced activity (glutamate, 4.69 
0.43 ms; homoquinolinate, 6.17 0.50 ms; p 0.0060; paired t test; n 7). SQRT, Square
root.
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channel activations evoked by glutamate or homoquinolinate
(log likelihood per event: glutamate, 4.97 0.03; homoquinoli-
nate, 4.94  0.03). Table 2 compares the mean (SEM) rate
constants for activations by glutamate or homoquinolinate fitted
to scheme 1. The fitted rate constants show that only the “slow”
(hypothesized NR2-dependent) activation rate (Banke and
Traynelis, 2003; Erreger et al., 2005) changes significantly for
scheme 1, consistent with the hypothesis that the identity of the
agonist bound to the NR2A subunit controls the rate of a slower
conformational change required for gating.
Macroscopic NR1/NR2A current responses to glutamate
or homoquinolinate
Partial agonists by definition produce reduced response com-
pared with a full or prototypical agonist. If our analysis of single-
channel records is correct to a first approximation, then we
should be able to predict the relative degree of partial agonism
from the rate constants derived from steady-state, single-channel
records. To directly evaluate the ability of gating rate constants
derived from fitted single-channel data to accurately describe
peak open probability and the time course of macroscopic cur-
rents, we first recordedmacroscopic currents in response to rapid
application of glutamate or homoquinolinate to excised outside-
out patches. Three sets of responses were generated for each ag-
onist (Fig. 8B,C), including (1) saturating agonist concentration
applied for 1 s, (2) saturating agonist concentration applied for
5–15ms, and (3) subsaturating agonist concentration applied for
1 s. The response for each patch to prolonged application of the
high (1 mM) agonist concentration response was normalized to
themeasured peak open probability of NR1/NR2A in response to
glutamate in one channel patch (0.50) (Erreger et al., 2005), and
responses averaged across patches for all three protocols.
Homoquinolinate-evoked responses in each patch were scaled to
the relative openprobability (0.31) calculated from the peak open
probability to glutamate (0.50) and the relative efficacy of homo-
quinolinate (62%) determined in outside-out patches in re-
sponse tomaximal concentrations of glutamate and homoquino-
linate (see above) (Fig. 1B), and averaged across patches. All three
curves for each agonist were then fitted simultaneously with
scheme 2 (Fig. 8A) with the gating rates fixed to those determined
from single-channel analysis. Scheme 2 incorporated two explicit
binding steps for glutamate or homoquinolinate as well as two
desensitization steps given the dual exponential time course for
desensitization; binding and desensitization parameters were free
to vary in these fits. Scheme 2 produced excellent fits to the mac-
roscopic peak open probability and time course, suggesting that
our single-channel measurements accurately describe the inde-
pendently recorded peakmacroscopic response (Fig. 8C). Table 2
summarizes the results from fitting scheme 2 tomacroscopic data
for both glutamate and homoquinolinate and confirms that an
independent subunit gating model with two pregating steps can
accurately predict themagnitude and time course ofmacroscopic
currents over a range of agonist concentrations and application
durations, as well as generate the experimentally determined
peak open probability. Furthermore, simulations show that the
time constant describing deactivation is virtually identical
(33.3–34 ms) for 1, 5, 10, 15, and 20 ms pulses of glutamate,
confirming that the application duration we chose did not con-
found determination of rate constants. Fitted data in Table 2 also
show a reduced association rate for homoquinolinate, an in-
creased KD, and an accelerated dissociation rate, consistent with
predictions from MD simulations.
Discussion
There are three main findings of this study. First, homoquinoli-
nate is a low-affinity partial agonist at NR1/NR2A receptors with
predicted increased intrapocket motion relative to glutamate.
Second, NR1/NR2A receptors activated by glutamate open faster
and have a higher open probability than those activated by the
Table 2. HiddenMarkovmaximum likelihood fitting of channel data and least-
squares fitting of macroscopic data
Units Glutamate Homoquinolinate % change
Single channels
kf s1 2559 280 2468 196 3.6
kf s1 1978 288 3005 696 51.9
ks s1 234 22 184 12 21.1*
ks s1 926 139 896 149 3.2
ko s1 5008 647 5822 899 16.3
ko s1 790 66 740 54 6.3
Macroscopic
kd1 s1 20 22
kd1 s1 0.76 0.71
kd2 s1 7.5 68
kd2 s1 6.7 45
kon M
1 s1 10.4 2.5
koff s
1 73 149
KD M 7.0 60
The sequence of openings and closing of single-channel records from individual patches were analyzed and fitted
with scheme 1 (Fig. 7). f and s refer to a “fast” and “slow” pregating step, hypothesized to reflect conformational
changes with NR1 and NR2 required for gating, respectively. Agonist binding and desensitization rates were not fit
because these records were recorded under supramaximal agonist concentration and segmented to remove desen-
sitized closed times. The meanSEM rate constant for each step is shown (n 7); on average, 13,384 and 6410
channel dwell times per patch were fitted for glutamate and homoquinolinate, respectively. Subsequent fitting of
macroscopic currents (Fig. 8) to scheme 2 with kf, kf, ks, ks, ko, ko all fixed to values determined
above was used to determine binding and desensitization constants. KD koff/kon.
*p 0.0085; paired t test.
Figure 7. Maximum interval likelihood fitting of steady-state activations of NR1/NR2A.
Steady-state currents were idealized and fit to a kinetic model that includes two independent
activation steps. A, Scheme 1 hypothesizes that these two independent pregating activation
steps involve a fast NR1-dependent step f and a slow NR2-dependent step s. Recordings were
performed in thepresenceof a saturating concentrationof agonist anddivided into segments to
remove desensitization. Therefore, explicit agonist binding and desensitization rates (gray ar-
rows) are not included in themodel.B, Dwell-time distribution histograms are shown for open
and shut times in a patch in which channel activity was evoked by 1 mM glutamate. The solid
lines show probability density functions predicted by the fit of the model to the sequence of
channel openings. A summary of the fitting results is given in Table 2. SQRT, Square root.
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partial agonist homoquinolinate, despite identical single-channel
chord conductance and mean open time. Third, we hypothesize
that helix F in the S2 domain of NR2A appears well positioned to
translate the effects of agonist binding to regions of the receptor
that control channel gating.
MD simulations suggest that glutamate and homoquinolinate
interact differently with the agonist binding pocket of NR2A. In
particular, residues interacting with the carboxylates are signifi-
cantly displaced by homoquinolinate from their location when
glutamate is bound. This modeling prediction was experimen-
tally verified by the finding that the apparent affinity of homo-
quinolinate is less sensitive to mutations predicted to interact
with the carboxylates of glutamate. The increasedmotion of por-
tions of the binding pocket around homoquinolinate may ex-
plain why the experimental KD value is higher for homoquinoli-
nate (60 M) than for glutamate (7 M). These KD values can be
used to estimate a standard free energy change for equilibrium
binding of homoquinolinate (5.76 kcal/mol) and glutamate
(7.03 kcal/mol).
Comparison of the apo, glutamate-bound, and homo-
quinolinate-bound states reveals not only that helix F in the S2 do-
main is significantly displaced by glutamate binding but also that it
becomes decoupled from local secondary structure elements after
homoquinolinatebinding.This decouplingdoesnotoccurwith glu-
tamate binding, suggesting that movement of helix F may exert
strain on critical elements for transducing agonist binding to chan-
nel gating and that this processmaybe compromised by the changes
in the binding pocket induced by the conformationally restrained
partial agonist homoquinolinate.
Patch-clamp recording revealed that the single-channel con-
ductance, mean channel open time, and rates governing desensi-
tization were unaffected by homoquinolinate compared with
glutamate but that channels activate more slowly in response to
homoquinolinate than to glutamate. This is consistent with the
hypothesis that agonist binding controls a pregating conforma-
tional change for each subunit but that stability and size of the
channel pore reflects a concerted global conformational change
not directly dependent on the conformation of the agonist bind-
ing domain. These results are all compatible with a physical
model of activation that includes at least two obligatory confor-
mational changes that precede gating, one of which is controlled
by agonist binding to the NR2 subunit and perhaps involves the
displacement of helix F in the S2 domain.
Mechanism of partial agonism at glutamate receptors
Although the concept of partial agonism was developed more
than 50 years ago (Ariens, 1954; Stephenson, 1956; Del Castillo
and Katz, 1957), only recently has an understanding of the struc-
tural and functional basis of partial agonism been elucidated for
at least one receptor, the AMPA subtype of glutamate receptors.
It has been shown for AMPA receptors that partial agonists in-
duce only partial closure of the agonist-binding S1S2 domain
purified in isolation from the receptor (Armstrong and Gouaux,
2000), suggesting that partial agonism in some ways reflects the
ability of different structural agonists to induce distinct receptor
domain conformations. Functionally, activation of AMPA recep-
tors by any agonist induces multiple conductance levels, and ev-
idence exists that the permeation properties of each conductance
level may be independent of the structure of the agonist. It has
been proposed that each AMPA receptor subunit can gate inde-
pendently and make an incremental contribution to ion perme-
ation (Rosenmund et al., 1998; Smith et al., 2000). This impor-
tant result drove the compelling convergence of structure and
function achieved by Jin et al. (2003), who demonstrated that the
degree of domain closure of the S1S2 domain in GluR2 induced
by partial agonists that differ by only a single atom correlates
directly with the functional efficacy for coupling agonist binding
to channel gating. However, there is evidence that the glycine
binding domain of NR1 does not exhibit a similar correlation
between domain closure and agonist efficacy (Furukawa and
Gouaux 2003; Inanobe et al., 2005).
Unlike AMPA receptors, NMDA receptors must be fully li-
ganded to open. There is evidence that multiple conformational
changes are required to transduce agonist binding into channel
gating (Banke and Traynelis, 2003; Popescu and Auerbach, 2003;
Popescu et al., 2004). AlthoughNMDAreceptor activation is thus
distinct from that of AMPA receptors (Erreger et al., 2004), there
are still important precedents operating for AMPA receptors that
hold implications for NMDA receptors. For example, both
AMPA and NMDA receptor subunits can contribute kinetically
distinct features to channel activation, suggesting that individual
NMDAreceptor subunits can have independent effects on gating.
In addition, Armstrong and Gouaux (2000) first showed that
partial agonism at AMPA receptors involves at least some degree
of altered protein conformation. Whereas direct empirical struc-
Figure 8. Least-squares fitting of a model of activation to macroscopic currents in response
to rapid agonist application. A, Scheme 2 is an extension of scheme 1 with explicit agonist
binding and desensitization rates. The rates for f,, s,, and o, (gray arrows) were
fixed to the values determined from single-channel analysis. The rates for agonist binding (kon,
koff) and desensitization (d1,, d2,)were varied by a simplex algorithm (least-squares
criterion). d1 and d2 represent entry into desensitized states, and d1 and d2 repre-
sent recovery from desensitized states. B, Representative macroscopic currents recorded in
outside-out patches excised from HEK293 cells expressing NR1/NR2A and held at a potential of
60mVare shown for eachof the threeprotocols: 1mM/1 s, 1mM/8ms, 5M/1 s for glutamate
(left) and 1 mM/1 s, 1 mM/8 ms, 30 M/1 s for homoquinolinate (right). The insets show the
responses evoked by brief (8 ms) 1 mM glutamate or homoquinolinate application on an ex-
panded time scale with the junction current (top trace) used to determine the time course of
solution exchange. C, The results of the simultaneous fitting of the scheme 2 shown in A to the
macroscopic current data sets in B are shown as solid black lines, with the mean experimental
normalized currents shown in gray (n 10). The results of fitting scheme 2 to themacroscopic
data are given in Table 2.
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tural data on agonist binding to NR2A are unavailable, our MD
docking simulations intimate that homoquinolinate and gluta-
mate induce different conformations within the binding cleft. In
particular, MD analysis of agonist docking suggests that homo-
quinolinate, a constrained analog of glutamate, engages in a sig-
nificantly different set of interactions within the binding domain
and thereby stimulates a qualitatively variable response from the
protein by comparison with glutamate. Thus, the different con-
formations induced by the glutamate- and homoquinolinate-
bound agonist binding domains may control efficacy. The diver-
gent efficacies could reflect global perturbation in the structure of
the agonist binding domain when homoquinolinate is docked
(Fig. 2, helix F). Alternatively, the partial agonism of homo-
quinolinate may imply increased intraprotein motion and de-
creased stability of the binding pocket (Fig. 5), which might not
spend as much time in the fully closed conformation hypothe-
sized to activate the ion channel. Although we cannot yet distin-
guish between these twohypotheses, the combined structural and
functional approach described here helps define more clearly the
molecular basis of partial agonism for NMDA receptors.
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